Ropidoxuridine

N/A

Report date: 2025/12/19 20:01:35
NME

Base Information

Drug NameRopidoxuridine
Drug Alias Nameropidoxuridina罗匹尿苷脱氧碘苷ropidoxuridinum5-Iodo-2-pyrimidinone 2'' deoxyribonucleoside +[12] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionThymidine kinase inhibitorsDNA synthesis inhibitors
TargetsThymidine kinase
Therapy Area/IndicationsBrain metastasesSolid tumoursUterine Cervical Neoplasms +[18] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesYale UniversityCentral State University Of New York Inc
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesShuttle Pharmaceuticals Inc
Active IndicationsBrain metastasesSolid tumoursUterine Cervical Neoplasms +[16] 
Inactive IndicationsGlioblastomaNeoplasms

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG